Charles Schwab Investment Management Inc. Trims Stake in InMode Ltd. (NASDAQ:INMD)

Charles Schwab Investment Management Inc. reduced its stake in InMode Ltd. (NASDAQ:INMD) by 13.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 183,777 shares of the healthcare company’s stock after selling 29,332 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.22% of InMode worth $3,069,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of INMD. Systematic Financial Management LP raised its stake in shares of InMode by 13.3% in the third quarter. Systematic Financial Management LP now owns 982,111 shares of the healthcare company’s stock worth $16,647,000 after buying an additional 115,492 shares during the period. Barclays PLC increased its holdings in InMode by 113.5% in the 3rd quarter. Barclays PLC now owns 169,630 shares of the healthcare company’s stock worth $2,876,000 after acquiring an additional 90,173 shares in the last quarter. Hotchkis & Wiley Capital Management LLC raised its stake in InMode by 12.9% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 720,750 shares of the healthcare company’s stock worth $12,217,000 after acquiring an additional 82,100 shares during the period. State Street Corp lifted its holdings in InMode by 3.7% during the third quarter. State Street Corp now owns 2,044,640 shares of the healthcare company’s stock valued at $34,657,000 after purchasing an additional 73,183 shares in the last quarter. Finally, Marathon Asset Management Ltd boosted its position in shares of InMode by 57.4% in the fourth quarter. Marathon Asset Management Ltd now owns 182,349 shares of the healthcare company’s stock worth $3,045,000 after purchasing an additional 66,475 shares during the period. 68.04% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently commented on INMD shares. Barclays raised their price objective on shares of InMode from $26.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday, February 5th. Needham & Company LLC restated a “hold” rating on shares of InMode in a research report on Tuesday, February 4th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, InMode presently has an average rating of “Hold” and a consensus price target of $22.25.

InMode Stock Performance

Shares of NASDAQ:INMD opened at $18.30 on Friday. The firm has a market cap of $1.27 billion, a price-to-earnings ratio of 7.79 and a beta of 2.08. The firm has a fifty day moving average price of $18.30 and a 200 day moving average price of $17.75. InMode Ltd. has a fifty-two week low of $14.87 and a fifty-two week high of $21.92.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.